David Fajgenbaum: It’s a common misconception that approval marks the peak of a drug’s journey
David Fajgenbaum shared on X:
“When a drug receives FDA approval, its research and development (R&D) often shifts away from further exploration into new indications.
It’s a common misconception that approval marks the peak of a drug’s journey.
In reality, it’s the opposite.
When the drug eventually turns generic, it becomes more affordable and accessible than ever. Yet paradoxically, this is when R&D typically comes to a standstill.
As someone whose life was saved by an old, generic drug, I am deeply invested in this topic. We should be maximizing these opportunities, not diminishing them.
At Every Cure, we are on a mission to shift the narrative and focus on how we can leverage these accessible drugs to their fullest potential.
What are your thoughts on how we can reinvigorate R&D for generic drugs to enhance their impact and accessibility?”
Source: David Fajgenbaum/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023